Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Elicio Therapeutics, Inc. (ELTX : NSDQ)
 
 • Company Description   
Elicio Therapeutics is a privately-held clinical-stage biotechnology company. It involved in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. Elicio Therapeutics, formerly known as Angion Biomedica Corp, is based in BOSTON.

Number of Employees: 32

 
 • Price / Volume Information   
Yesterday's Closing Price: $8.27 Daily Weekly Monthly
20 Day Moving Average: 44,327 shares
Shares Outstanding: 16.00 (millions)
Market Capitalization: $132.29 (millions)
Beta: 1.16
52 Week High: $9.99
52 Week Low: $3.70
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 3.12% -0.74%
12 Week 73.74% 46.14%
Year To Date 62.16% 51.86%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
451 D Street 5th Floor
-
Boston,MA 02210
USA
ph: 857-209-0050
fax: -
ir@elicio.com http://www.elicio.com
 
 • General Corporate Information   
Officers
Robert Connelly - Chief Executive Officer and President
Jay Venkatesan - Director
Julian Adams - Director
Carol Ashe - Director
Karen Wilson - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 28657F103
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/12/25
Share - Related Items
Shares Outstanding: 16.00
Most Recent Split Date: 6.00 (0.10:1)
Beta: 1.16
Market Capitalization: $132.29 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.63 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.58 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 14.82
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 24.35%
vs. Previous Quarter: 14.71%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -185.70
12/31/24 - -194.65
Current Ratio
06/30/25 - -
03/31/25 - 1.83
12/31/24 - 1.80
Quick Ratio
06/30/25 - -
03/31/25 - 1.83
12/31/24 - 1.80
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 0.56
12/31/24 - -1.03
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - -
 

Powered by Zacks Investment Research ©